Europe CGM market to top $9B
The Europe blood‑glucose‑monitoring market is projected to exceed USD 9 billion by 2031, driven by CGM expansion, remote care integration, and falling CGM costs — a major commercial tailwind for diabetes tech companies GlobeNewswire report. Expect increased investment in digital care platforms and payer negotiations.
The GlobeNewswire‑posted market brief projects (supplychaindigital.com) the Europe blood‑glucose‑monitoring market to climb from USD 5.61 billion in 2025 to USD 9.04 billion by 2031 — an 8.28% compound annual growth rate. Analyst splits appear within that total: Mordor Intelligence forecasts Europe’s continuous‑glucose‑monitoring (CGM) market at USD 7.21 billion by 2031 with a 15.12% CAGR, reflecting a CGM‑focused segmentation. (mordorintelligence.com) By contrast, The Insight Partners’ CGM‑device forecast values the Europe CGM device market at roughly USD 9.94 billion by 2031, underlining methodological differences between market reports. (theinsightpartners.com) Major device incumbents named across the reports are F. Hoffmann‑La Roche (Roche), Abbott, Dexcom, Medtronic and Ascensia, which the market studies list as the principal competitors shaping regional share. (mordorintelligence.com) Reimbursement remains uneven: a King’s College London commentary concluded no European country offers unlimited CGM reimbursement, with national schemes typically limited to specific clinical indications. (kclpure.kcl.ac.uk) UK procurement documents and clinical policies show widening but conditional NHS access — pan‑London cost assumptions list about £29.76 per 14‑day sensor (April 2024 indicative price), while NHS clinical guidance classifies FreeStyle Libre variants among formulary options. (england.nhs.uk) Price and reimbursement pressure is visible in practice: the FreeStyle Libre 3 was added to the UK Drug Tariff for reimbursement in 2024, with trade reporting that pharmacy reimbursement mechanics can make the sensor loss‑making for some dispensers. (dmd-browser.nhsbsa.nhs.uk) Public and private funding channels are lining up behind digital diabetes care — the European Commission lists Horizon Europe, EU4Health and EIC programmes for digital‑health innovation, while sector analysts note VC markets cooled in 2024 but remain selective for diabetes platforms. (health.ec.europa.eu)
